A

Amgen

Makes biotech medicines for serious illnesses

Procurement Global Category Senior Manager-Medical Communications

Full-TimeUpdated on 10/24/2026
No salary listed
Expert
Bachelor's, Master's, MBA
Hyderabad, Telangana, India
In PersonOn-site in Hyderabad, India.
Operations & LogisticsProcurement & Sourcing

About the job

Requirements
  • Proven experience leading Medical Communications or Marketing Procurement categories end-to-end, from category strategy and business planning through sourcing, supplier management, and value realization.
  • Strong background in Medical Communications, Marketing Procurement, or related categories within biotechnology, pharmaceutical, healthcare, or other highly regulated industries, with an understanding of agency ecosystems.
  • Demonstrated ability to lead, inspire, and influence global, matrixed teams across business units, functions, and geographies.
  • Expertise in driving enterprise-wide sourcing strategies, leading complex supplier relationships, managing strategic trade-offs, and representing key categories in executive forums.
  • Deep understanding of agency and supplier ecosystems, with demonstrated success leveraging supplier-enabled innovation, emerging technologies, and artificial-intelligence-enabled communications solutions.
  • Outstanding communication, negotiation, and executive stakeholder management skills, with the ability to influence senior leaders, build consensus, and drive strategic decision-making.
  • Master’s degree and 8 years of business partnering, category management, and/or related experience, or bachelor’s degree and 13 years of business partnering, category management, and/or related experience.
  • In addition to meeting at least one of the degree-and-experience requirements, experience directly managing people and/or leadership experience leading teams, projects, programs, or directing the allocation of resources.
  • Executive presence and ability to influence effectively across senior leadership.
  • Exceptional written and verbal communication skills tailored for executive-level interactions.
  • Ability to collaborate with global, virtual teams.
  • Ability to navigate ambiguity and lead through change.
  • Self-motivation and a proactive, strategic mindset.
  • Ability to multitask and prioritize effectively.
  • Business acumen to balance commercial objectives, risk management, and stakeholder needs.
  • Collaborative approach focused on delivering enterprise value and achieving collective goals.
Responsibilities
  • Serve as a trusted advisor and thought leader for Medical Communications, collaborating across the creative agency category in Marketing as needed by providing expert insights into market dynamics, supplier capabilities, emerging communications technologies, and industry best practices.
  • Translate market and supplier insights into actionable category strategies that support enterprise reputation, stakeholder engagement, and business objectives.
  • Build strategic relationships with stakeholders across medical, commercial, marketing operations, and cross-functional teams to align business priorities with category strategies.
  • Use market intelligence to develop and execute category strategies across Medical, Medical Communications, and, as needed, creative agencies for content creation and related services, aligning work with enterprise priorities and measurable business value.
  • Provide procurement expertise across the Medical Communications ecosystem and, as needed, the creative agency space to advance strategic communications initiatives and enterprise transformation, positioning Procurement as a strategic partner.
  • Partner with Finance and cross-functional teams to guide investment and budget decisions while balancing stewardship, impact, innovation, and risk.
  • Align procurement performance with business goals through category initiatives that improve supplier governance, optimize investments, and deliver measurable outcomes across medical and marketing organizations.
Desired Qualifications
  • Advanced degree (MBA or equivalent), or significant professional experience in Medical or Marketing Communications or Agency Management.
  • Strong analytical mindset with expertise in supplier performance measurement, value realization, market intelligence, and business case development.
  • Experience with communications agency models and commercialization contracting frameworks.
  • Expertise in advanced Strategic Sourcing and Supplier Relationship Management methodologies.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.